Evaluation of serum replacement frequency used in drug infusion on serum contamination and incidence of phlebitis

Phase 3

Recruiting

• Conditions: Condition 1: Phlebitis. Condition 2: Catheter-related infection.; Vascular complications following a procedure, not elsewhere classified; Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts; T81.7; T85.7

• Registration Number: IRCT20210307050610N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

People over the age of 18
patient consent or caregiver
patient cooperation
having a drug to be infused
patients who have been hospitalized for at least 48 hours

Exclusion Criteria

Pregnant patients
lactating patients
immunocompromised patients
Patients with skin and vascular diseases
Patients receiving hypertonic serum
and patients receiving blood and blood products
patients receivingTotal parenteral nutrition
Patients with sepsis
patients with mental disorders
Patients receiving anticoagulants
If you have a local infection at the catheter injection site

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of phlebitis according to Jackson criteria. Timepoint: During the period of hospitalization. Method of measurement: Jackson criteria.;Number of cases of serum contamination. Timepoint: 24 hours in the control group and 48 hours in the experimental group. Method of measurement: Response of serum culture sample sent to laboratory.

Secondary Outcome Measures

Name	Time	Method
umber of catheter contamination cases. Timepoint: Discharge of the patient or 72 hours after catheter placement or catheter phlebitis. Method of measurement: Response of the catheter sample sent to the laboratory.